# 2021-2022 Ivy Biomedical Innovation Fund
# Review Board

**David L. Brautigan, Professor Emeritus of Microbiology, Immunology & Cancer Biology and the Center for Cell Signaling**

David's research specialty is the biochemistry of cell signaling by protein phosphorylation, involving protein phosphatase and kinase enzymes. Dr. Brautigan has published more than 200 scientific articles and served as principal investigator and co-investigator on research grants from the National Institutes of Health (NIH) and private foundations. He has evaluated federal research grant applications on a variety of NIH panels, and for 2010-2012 was elected chairman of the Molecular and Integrative Signal Transduction (MIST) study section. He serves as the co-leader of the Cancer Cell Signaling program and member of the executive committee at the UVA Cancer Center and was recently appointed as External Advisor of a Marie-Curie European Training Network, a consortium of academic groups and companies seeking to commercialize pharmacological regulators of protein phosphatases as cancer therapeutics. He has more than a dozen licensed research reagents in commercial distribution and has consulted for pharmaceutical and biotechnology companies for over 25 years.
David Brautigan received his B.A. degree at Kalamazoo College, a M.S. in chemistry and a Ph.D. in biochemistry from Northwestern University in Evanston, Illinois. He was a postdoctoral fellow at the University of Washington, Seattle with Nobel laureate Edmond H. Fischer. Before moving to Virginia in 1994 David was Professor of Medical Science at Brown University and served as Director of the Ph.D. program in Molecular, Cell Biology and Biochemistry

**Gerry Brunk, Managing Director, Lumira Capital**

Gerry focuses on investments in a range of therapeutic areas in the biotechnology and medical device sectors and manages Lumira Capital's Boston office, which he established when he joined the firm in 2002. Prior to joining Lumira Capital Gerry was an entrepreneur in the life sciences sector, founding and serving in a variety of management and board capacities at several venture capital-funded companies. Earlier in his career he was an engagement manager in the healthcare practice of The Boston Consulting Group and was a member of the investment banking group of Credit Suisse First Boston.
Gerry holds an MBA from Stanford University Graduate School of Business and a BA from the University of Virginia, where he studied biology and economics.

**Richard Chylla, Executive Director, UVA Licensing & Ventures Group**

Rich comes to the University of Virginia from the Innovation Center at Michigan State University where he served as Executive Director of MSU Technologies since 2012. He also served on the board of directors for the Association of University Technology Managers (AUTM) and held the AUTM chair position in 2019. He has more than 25 years of experience in university technology transfer, research leadership, and business development.
Rich has extensive experience in licensing and technology commercialization in both academic and industry settings. He has amassed career accomplishments with top-tier organizations including the University of Michigan and BASF Corporation. He also has broad international experience having worked in various technical roles with Johnson Polymer in Singapore, Japan, and the Netherlands.
At Michigan State, Rich was instrumental in launching two translational funds totaling $7M since 2014 in partnership with economic development agencies. These supported more than 160 projects to advance university technologies generating licenses with industry, new startups, and jobs. He doubled the number of licenses and options since 2013, grew the total licensing revenue, and strengthened relations between the university and the local entrepreneurial community. MSU Technologies grew the number of university startups launched each year and attracted more than $100M in follow-on capital.

**Nikki Hastings, PhD, Executive Director, CvilleBioHub**

Nikki Hastings is co-founder and managing partner of QDS Capital. She has over 15 years of experience with early stage biotech/medtech and medical device companies, specifically with expertise in working with academic and first-time founders. She has led operations in executive management roles at companies including HemoShear Therapeutics, Contraline, and Cerillo. Nikki co-founded and led a private non-profit organization, CvilleBioHub, supporting growth of the regional biotech industry in Central Virginia and was the organization's first executive director. Dr. Hastings is an adjunct faculty member in the UVA McIntire School of Commerce and holds a PhD in biomedical engineering from the University of Virginia. She has also served as the COO of Contraline and VP for Operations for Hemoshear.

**William McPheat, Mentor, Innovation Commercialization Assistance Program (ICAP), a program of George Mason University and the Virginia SBDC; Adjunct Faculty Eastern Virginia Medical School**

Willie brings over 25 year of drug discovery, development as principal scientist and project leader from his career at AstraZeneca. He has co-authored dozens of publications in areas such as inflammation, cardiovascular and infectious diseases. His expertise areas include: infection, inflammation, pulmonary hypertension and cardiovascular (atherosclerosis, diabetes) biology. Dr. McPheat has established and led collaborations with external academic groups and companies located in USA, France, Canada, Germany and China.
Current he serves as an adjunct faculty at Eastern Virginia Medical School, where he lectures on the economics and process of drug discovery to PhD and Master students. He is also a member of the VCU Commercialization Advisory Board and advises the Virginia Innovation Partnership (formerly named CIT). McPheat received his PhD from the University of Glasgow in microbiology and received his MBA from the College of William and Mary.

**Hina Mehta**
**Director, University Programs, Virginia Innovation Partnership Corporation**

Hina Mehta joined VIPC in 2022 as Director of University Programs for the Commercialization Division. In this role, she participates in the development and execution of the Commonwealth Commercialization Fund (CCF) grant programs and serves as the lead for promoting and managing the CCF's university-focused programs. Hina has extensive experience in research commercialization and was, during her tenure as Director of the Office of Technology Transfer at George Mason University, successful at engaging with and supporting commercialization-minded research faculty. At Mason, she also mentored faculty-led teams participating in customer discovery programs such as NSF I-Corps and ICAP.
Prior to Mason, Hina worked in biomedical research, in strategic consulting, and co-founded a startup. Hina is passionate about community service, serves on several innovation and entrepreneurship committees, and volunteers for nonprofit community organizations.
She holds a Ph.D. in Neuroscience from the Indian Institute of Chemical Biology, and an MBA from the University of Maryland.

**Robert Meyer, Principal, Drug and Biological Products at Greenleaf Health Inc.**

Dr. Robert Meyer, M.D., is currently a Principal in Drug and Biological Products at Greenleaf Health Inc. Formerly he served as the Director of the Virginia Center for Translational and Regulatory Sciences (VCTRS) and associate professor of Public Health Sciences. Through VCTRS, he is developed a regulatory science educational track, as well as provide regulatory and translational knowledge resources to University and external entities who seek to translate basic science discoveries to the bedside. Prior to UVA, Dr. Meyer was Vice President, Global Regulatory Strategy, Policy and Safety at Merck Research Laboratories (MRL), where he was responsible for all regulatory strategy and operations, global regulatory policy and intelligence, as well as global product safety and pharmacovigilance.
Externally, Dr. Meyer chaired the Regulatory Affairs Coordinating Committee for Pharmaceutical Research and Manufacturers of America (PhRMA) from 2012-13, and served as a key PhRMA negotiator on PDUFA V. Previously, Dr. Meyer worked for the U.S. Food and Drug Administration (FDA – 1994-2007). In his last 5 years at the FDA, Dr. Meyer was as the Director for the Office of Drug Evaluation II (ODEII) within Center for Drug Evaluation and Research (CDER), with responsibilities for pulmonary and allergy, metabolic and endocrine, and analgesics, anesthetics and rheumatologic drug products. Dr. Meyer was involved in several CDER initiatives, amongst them chairing the development of the Pre-Market Risk Assessment guidance. While at FDA and again at UVA, Dr. Meyer is as a technical expert to the Medical Aerosols Technical Options Committee to the Montreal Protocol on the Protection of the Ozone Layer, work for which he was recognized by both United Nations Environmental Programme and the US EPA.
Prior to joining FDA, Dr. Meyer was an academic pulmonologist and critical care specialist at the Oregon Health and Sciences University, where he helped create the medical service for the Lung/Heart-Lung Transplantation team. He received his medical degree.

**Kyparissia Sirinakis, Managing Partner, Epidarex Capital**

Ms. Sirinakis has more than twenty years of experience in creating and growing companies. She has a proven track record as an early-stage investor and senior executive in various technology and life science companies. Prior to co-founding Epidarex Capital, Ms. Sirinakis was part of the senior management team of MASA Life Science Ventures (MLSV), where she co-led MLSV's strategy and managed several MLSV portfolio investments through successful exits. Ms. Sirinakis was the Founder and Managing Director of WomenAngels.net LLC ("WAN"), a successful early-stage venture fund focused on the U.S. Mid-Atlantic region. Launched in 2000, WAN successfully invested in highly disruptive technology platforms developed by strong management teams targeting large and unmet market needs across a variety of industry sectors.
Ms. Sirinakis has extensive experience working in the university environment as the Director of a technology accelerator and Adjunct Professor at George Mason University. She was the CFO of Oncologix, a venture-backed, early-stage biotechnology company subsequently sold to Antigenics, Inc. Ms. Sirinakis has held numerous directorships of start-up companies throughout her career. She is a graduate of Boston College's School of Management Honors Program and a Certified Public Accountant in the State of Maryland.

Ad Hoc:

**Bob Creeden, Director, UVA Seed Fund & New Ventures, Licensing & Ventures Group**

Bob serves as the Managing Director of the UVA LVG Seed Fund & New Venture to manage the $20M UVA LVG Seed Fund I & II. Creeden has deployed $4.1M across nine portfolio companies with two exits and has leveraged more than $14.1M from syndicate

partners. He has launched several initiatives to identify opportunities for the creation of high-quality ventures based on UVA research assets including an Entrepreneurs in Residence program. The program successfully launched its first company, Slate Bio, in January 2021. Creeden recently completed the fifth year of the UVA LVG Seed Fund's accompanying course at UVA's Darden School of Business, Due Diligence in Seed Fund Investing. The course invites rising second-year students to learn industry-proven practices as they assist with company evaluations. With support from the Batten Institute at Darden, Creeden also offers a summer internship.
Prior to joining UVA LVG, Creeden served as the founding executive director of the Blackstone Entrepreneurs Network in the North Carolina Research Triangle. His efforts helped strengthen the area's business environment, resulting in early-stage and seed investment of more than $60M. Creeden holds a bachelor's degree in economics from Holy Cross College in Worcester, Massachusetts, and an M.B.A. from Suffolk University in Boston.

**Kuldeep Neote, NIH Entrepreneur-in-Residence (EIR), Small Business Education and Entrepreneurial Development (SEED), past Eli Lilly and Johnson and Johnson**

Kuldeep, earned his PhD in Molecular Genetics at the University of Toronto. He has over 25 years in the life science industry, including as a researcher at Genentech, Pfizer, and Eli Lilly and Company, and as a business development executive at Johnson & Johnson and Eli Lilly and Company. He is currently an Entrepreneur-in-Residence at FACIT/OICR in Toronto and at The National Institutes of Health in Maryland. He is the Chair, Scientific Advisory Board for GeneTether Therapeutics.

During his time at Pfizer where he was responsible for initiating the chemokine drug discovery program. Kuldeep is well published and holds several patents.
During his postdoctoral work at Genentech from 1991 to 1994 focused on chemokine biology and he cloned the first CC chemokine receptor.

**Sean Moore, Chief of the Division of Pediatric Gastroenterology, Nutrition, & Hepatology, University of Virginia, Co-Director of the TransUniversity Microbiome Initiative**

Dr. Sean Moore, M.D. is a physician-scientist with training in pediatrics, gastroenterology, global health, and cell biology. He joined the Department of Pediatrics at UVa in 2016 as Director of Research for the Division of Pediatric Gastroenterology, Hepatology, & Nutrition and in 2020 became the Chief of the Division of Pediatric Gastroenterology, Nutrition, & Hepatology. The Moore Laboratory works at the dynamic intersection of childhood nutrition, gut health, and enteric microbes. He also serves as the Co-Director of the TransUniversity Microbiome Initiative and as the director of UVA's iTHRIV Pilot Studies Program.